6 LIBERTY SQUARE, BOSTON, MA
News, Articles of Incorporation
Amended material disclosure
Develops TTX-MC138 for Metastatic Disease
Announces the acquisition of Polynoma and a $25 Million strategic financing to form a first-in-class unique immuno-oncology and metastatic prevention oncology company
Material Contracts
Shareholder votes
Shareholder Director Nominations
Q2
Q1
FY 2024
Notice of Late Filing for Annual Report
Q3
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Notice of Exempt Offering of Securities
S-1
Prospectus filed pursuant to Rule 424(b)(4)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Schedule 13D - Ownership Report
Statement of Changes in Beneficial Ownership
Definitive Revised Proxy Statement